Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Breast. 2019 Feb;43:55-58. doi: 10.1016/j.breast.2018.11.004. Epub 2018 Nov 9.
The objective of this study was to evaluate ipsilateral breast tumor recurrence (IBTR) rates in patients with small (≤1 cm) ductal carcinoma in situ (DCIS) who were followed up for more than 15 years.
We identified 209 patients with primary small (≤1 cm) DCIS without invasion who received curative excision with and without adjuvant radiation therapy (RT) from 1996 to 2009. IBTR rates and prognostic factors in all patients were estimated by univariate and multivariate analyses.
With a median follow-up of 104 months, eight (53.3%) had DCIS recurrence and seven (46.7%) had recurrence of invasive ductal carcinoma. IBTR rate of all patients was 7.5% at 10 years and 12.1% at 15 years. In univariate analysis, age and subtypes were significant factors for IBTR. In multivariate analysis, resection margin, adjuvant RT, and endocrine therapy were significant factors for IBTR.
IBTR rate of small (≤1 cm) DCIS following excision with or without adjuvant RT was 12.1% at 15 years. Adjuvant RT and endocrine therapy were associated with lower IBTR rate in small DCIS.
本研究旨在评估随访时间超过 15 年的直径≤1cm 乳腺导管原位癌（DCIS）患者同侧乳腺肿瘤复发（IBTR）的发生率。
我们从 1996 年至 2009 年期间，共纳入 209 例接受根治性切除且无侵袭性的原发性直径≤1cm DCIS 患者，其中部分患者接受了辅助放疗（RT）。通过单因素和多因素分析评估所有患者的 IBTR 率及预后因素。
中位随访时间为 104 个月，8 例（53.3%）患者发生 DCIS 复发，7 例（46.7%）患者发生浸润性导管癌复发。所有患者的 10 年 IBTR 率为 7.5%，15 年 IBTR 率为 12.1%。单因素分析显示，年龄和亚型是 IBTR 的显著影响因素。多因素分析显示，切缘、辅助 RT 和内分泌治疗是 IBTR 的显著影响因素。
接受根治性切除且或不接受辅助 RT 的直径≤1cm DCIS 患者的 15 年 IBTR 率为 12.1%。辅助 RT 和内分泌治疗可降低小 DCIS 的 IBTR 率。
